Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML

Yngvar Floisand, MD PhD, Iris Bigalke, MD, Dag Josefsen, MD PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Richard Addo, MD PhD, Dolores J. Schendel, PhD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-139255

Published: 2020

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Iris Bigalke, MD, Judith Eckl, PhD, Guri Solum, MSc, Kirsti Hønnåshagen, Msc, Lisbeth Skoge, MSc, Yngvar Fløisand, MD PhD, Dag Josefsen, MD PhD, Stein Sæbøe-Larssen, PhD, Christiane Geiger, PhD, Dolores Schendel, PhD, Gunnar Kvalheim, MD PhD

Blood (2018) 132 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2018-99-114557

Published: 2018

Journal Articles

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

Dag Josefsen, MD PhD, Yngvar Fløisand, MD PhD, Harald Holte, Jr., MD PhD, Gunnar Kvalheim, MD PhD

Blood (2016) 128 (22): 5826.

https://doi.org/10.1182/blood.V128.22.5826.5826

Published: 2016

Journal Articles

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Felix S. Lichtenegger, MD, Katrin Deiser, PhD, Maurine Rothe, Frauke M. Schnorfeil, PhD, Christina Krupka, PhD, Christian Augsberger, Thomas Köhnke, MD, Veit L. Bücklein, MD, Torben Altmann, MD, Andreas Moosmann, Monika Brüggemann, MD PhD, Mirjam H.M. Heemskerk, PhD, Georg Wittmann, MD, Beate Wagner, MD, Wolfgang Hiddemann, MD, Iris Bigalke, PhD, Gunnar Kvalheim, MD PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 764.

https://doi.org/10.1182/blood.V128.22.764.764

Published: 2016

Journal Articles

AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome

Iris Bigalke, Yngvar Fløisand, MD PhD, Guri Solum, Kirsti Hønnåshagen, Marianne Lundby, Kristina Anderson, MD PhD, Stein Sæbøe-Larssen, PhD, Else-Marit Inderberg, PhD, Judith Eckl, PhD, Dolores J Schendel, PhD, Gunnar Kvalheim, MD PhD

Blood (2015) 126 (23): 3798.

https://doi.org/10.1182/blood.V126.23.3798.3798

Published: 2015

Journal Articles

Vaccination with a New Generation of Fast Dendritic Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount Strong Immune Responses and Prolong Survival

Iris Bigalke, MD, Kirsti Honnashagen, Marianne Lundby, Julitta Kasten, Else Marit Suso Inderberg, PhD, Lisbeth Skoge, Stein Saboe-Larssen, PhD, Dolores J Schendel, PhD, Gunnar Kvalheim, MD PhD

Blood (2014) 124 (21): 2440.

https://doi.org/10.1182/blood.V124.21.2440.2440

Published: 2014

Journal Articles

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Blood (2013) 122 (21): 4195.

https://doi.org/10.1182/blood.V122.21.4195.4195

Published: 2013

Journal Articles

The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival

Dag Josefsen, MD, PhD, Geir Hetland, MD, PhD, Yngvar Fløisand, MD, Ph.D, Harald Holte, MD, PhD, Gunnar Kvalheim, MD, PhD

Blood (2013) 122 (21): 5517.

https://doi.org/10.1182/blood.V122.21.5517.5517

Published: 2013

Journal Articles

Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients

Gunnar Kvalheim, MD, PhD, Iris Bigalke, MD, Siri Torhaug, MD, Marianne Lundby, Camilla Mollat, Else-Marit Inderberg Suso, PhD, Arne Kolstad, MD, PhD, Gustav Gaudernack, PhD, Anne-Marie Rasmussen, PhD, Steinar Aamdal, MD, PhD

Blood (2013) 122 (21): 4487.

https://doi.org/10.1182/blood.V122.21.4487.4487

Published: 2013

Journal Articles

Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade

Felix S Lichtenegger, MD, Barbara Beck, PhD, Christiane Geiger, PhD, Dieter Munker, Miriam Schlueter, Rika Draenert, MD, Frauke Schnorfeil, PhD, Gunnar Kvalheim, MD, PhD, Wolfgang Hiddemann, M.D., Dolores J Schendel, PhD, Marion Subklewe, MD

Blood (2013) 122 (21): 3492.

https://doi.org/10.1182/blood.V122.21.3492.3492

Published: 2013

Journal Articles

A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response

Arne Kolstad, MD, PhD, Shraddha Kumari, PhD, Gunnar Kvalheim, MD, PhD, Trond Velde Bogsrud, MD, PhD, Ulf Madsbu, MD, Trond Hagtvedt, MD, Gustav Gaudernack, MD, Grethe Lauvvang, RN, Harald Holte, MD, PhD, Johanna Olweus, MD, PhD

Blood (2010) 116 (21): 1804.

https://doi.org/10.1182/blood.V116.21.1804.1804

Published: 2010

Journal Articles

T Cell Responses in Patients Vaccinated with Telomerase (hTERT)-mRNA Transfected Dendritic Cells.

Else Marit Inderberg Suso, Phd, fellow, Anne-Marie Rasmussen, PhD, Steinar Aamdal, MD, PhD, Svein Dueland, MD, PhD, Gustav Gaudernack, PhD, Gunnar Kvalheim, MD, PhD

Blood (2009) 114 (22): 373.

https://doi.org/10.1182/blood.V114.22.373.373

Published: 2009

Journal Articles

Mesenchymal Stem Cell Therapy in a Rat Model for GvHD

Severin Zinöcker, Mengyu Wang, Janne Nestvold, PhD, John Torgils Vaage, MD, PhD, Gunnar Kvalheim, MD, PhD, Bent Rolstad, MD, PhD

Blood (2008) 112 (11): 4620.

https://doi.org/10.1182/blood.V112.11.4620.4620

Published: 2008

Journal Articles

RNA Based Cancer Vaccines - Clinical Trials in Patients with Prostate Cancer and Malignant Melanoma.

Gunnar Kvalheim, MD, PhD, Steinar Aamdal, MD, PhD, Gustav Gaudernack, PhD

Blood (2007) 110 (11): 1805.

https://doi.org/10.1182/blood.V110.11.1805.1805

Published: 2007

Journal Articles

Optimizing Culture Conditions for Ex Vivo Expansion of Virus Specific T Cells.

Gabriel Borelli, MD, Tanja Aarvak, PhD, Anne Brunsvig, Marianne Dyrhaug, Marianne Lundby, Hege Hammerstad, Anne Marie Rasmussen, PhD, Gunnar Kvalheim, MD, PhD

Blood (2007) 110 (11): 4863.

https://doi.org/10.1182/blood.V110.11.4863.4863

Published: 2007

Journal Articles

Characterization of a Bone Marrow Derived Mesenchymal Cell Line from Nude Rat Assembling Tumor Stem/Progenitor Cell Properties In Vitro and In Vivo.

Mengyu Wang, MD, Jingfang Ju, Ph.D, Stein Saeboe-Larssen, Ph.D, Svein-Ole Mikalsen, Ph.D, Elena Olsen, Jahn M. Nesland, MD, Ph.D, Oystein Fodstad, MD, Ph.D, Gunhild Maelandsmo, Ph.D, Gunnar Kvalheim, MD, PhD

Blood (2006) 108 (11): 4256.

https://doi.org/10.1182/blood.V108.11.4256.4256

Published: 2006

NARROW

A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome

Vaccination with a New Generation of Fast Dendritic Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount Strong Immune Responses and Prolong Survival

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival

Clinical and Immunological Response Following hTERT/Survivin mRNA-Loaded Dendritic Cell Vaccination Combined With Ex-Vivo Expanded T Cell Transfer In Melanoma Patients

Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade

A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response

T Cell Responses in Patients Vaccinated with Telomerase (hTERT)-mRNA Transfected Dendritic Cells.

Mesenchymal Stem Cell Therapy in a Rat Model for GvHD

RNA Based Cancer Vaccines - Clinical Trials in Patients with Prostate Cancer and Malignant Melanoma.

Optimizing Culture Conditions for Ex Vivo Expansion of Virus Specific T Cells.

Characterization of a Bone Marrow Derived Mesenchymal Cell Line from Nude Rat Assembling Tumor Stem/Progenitor Cell Properties In Vitro and In Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only